JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
McKesson Corporation (NYSE:MCK)’s stock has reached a new all-time high, hitting $737.0 USD. With a market capitalization of $92 billion, this healthcare giant continues to demonstrate robust performance. Over the past year, its stock value has increased by an impressive 25.31%, supported by strong revenue growth of 16.22%. According to InvestingPro analysis, the stock appears fairly valued at current levels, with analyst price targets ranging up to $820. The healthcare giant’s stock has been on an upward trajectory, benefiting from strong financial results and strategic initiatives that have bolstered investor confidence. InvestingPro data reveals the company maintains a "GREAT" financial health score, with management actively buying back shares and the stock showing historically low price volatility. This new peak reflects the market’s positive sentiment towards McKesson’s growth prospects and its ability to navigate the evolving healthcare landscape effectively. Discover 14 additional exclusive insights about McKesson with an InvestingPro subscription.
In other recent news, McKesson Corporation reported strong earnings for Q3 2025, with an adjusted earnings per share (EPS) of $10.12, surpassing the forecast of $9.81. However, the company’s revenue fell short of expectations, coming in at $90.82 billion against a forecast of $93.48 billion. McKesson also announced the completion of its acquisition of a 70% controlling interest in Core Ventures, valued at approximately $2.49 billion, as part of its strategy to enhance community-based oncology care. Morgan Stanley (NYSE:MS) raised its price target for McKesson to $770, maintaining an Overweight rating, while Jefferies increased its target to $800, reiterating a Buy rating, both reflecting confidence in McKesson’s growth prospects. Meanwhile, Wells Fargo (NYSE:WFC) maintained an Equal Weight rating with a $766 price target, following a slight increase in McKesson’s full-year EPS guidance. McKesson’s strategic focus includes divesting its MedSurg segment, aligning with its core portfolio management strategy. The company’s long-term EPS growth outlook remains between 12% and 14%, with a focus on strengthening its core U.S. Pharmaceutical (TADAWUL:2070) segment. These developments underscore McKesson’s ongoing efforts to focus on its primary business areas and drive growth in the healthcare services sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.